1932

Abstract

The prevalence of atrial fibrillation (AF) has risen significantly over the past two decades. Catheter ablation is an increasingly utilized treatment strategy and has evolved significantly over the same time period. Successful ablation improves patient symptoms, reduces stroke risk, and can preserve or improve cardiac function. Recurrences following ablation can occur, particularly in patients with persistent AF. Procedural efficacy can best be improved through continued advancements in ablation technology and strategy, better understanding of the mechanisms of AF initiation and perpetuation, and rigorous integration of ablation into a multidisciplinary AF management approach.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-041316-090015
2018-01-29
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/med/69/1/annurev-med-041316-090015.html?itemId=/content/journals/10.1146/annurev-med-041316-090015&mimeType=html&fmt=ahah

Literature Cited

  1. Kneeland PP, Fang MC. 1.  2009. Trends in catheter ablation for atrial fibrillation in the United States. J. Hosp. Med. 4:E1–5 [Google Scholar]
  2. Freeman JV, Wang Y, Akar J. 2.  et al. 2017. National trends in atrial fibrillation hospitalization, readmission, and mortality for Medicare beneficiaries, 1999–2013. Circulation 135:1227–39 [Google Scholar]
  3. Miyasaka Y, Barnes ME, Gersh BJ. 3.  et al. 2006. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.. Circulation 114:119–25 [Google Scholar]
  4. Go AS, Hylek EM, Phillips KA. 4.  et al. 2001. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–75 [Google Scholar]
  5. Colilla S, Crow A, Petkun W. 5.  et al. 2013. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am. J. Cardiol. 112:1142–47 [Google Scholar]
  6. Rich MW. 6.  2009. Epidemiology of atrial fibrillation. J. Interv. Cardiac Electrophysiol. 25:3–8 [Google Scholar]
  7. Santangeli P, Di Biase L, Mohanty P. 7.  et al. 2012. Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. J. Cardiovasc. Electrophysiol. 23:687–93 [Google Scholar]
  8. Cappato R, Calkins H, Chen SA. 8.  et al. 2010. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3:32–38 [Google Scholar]
  9. January CT, Wann LS, Alpert JS. 9.  et al. 2014. AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation 130:232071–104 [Google Scholar]
  10. Wazni OM, Marrouche NF, Martin DO. 10.  et al. 2005. Radiofrequency ablation versus antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293:2634–40 [Google Scholar]
  11. Oral H, Pappone C, Chugh A. 11.  et al. 2006. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N. Engl. J. Med. 354:934–41 [Google Scholar]
  12. Bunch TJ, May HT, Bair TL. 12.  et al. 2013. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 10:1272–77 [Google Scholar]
  13. Jongnarangsin K, Suwanagool A, Chugh A. 13.  et al. 2012. Effect of catheter ablation on progression of paroxysmal atrial fibrillation. J. Cardiovasc. Electrophysiol. 23:9–14 [Google Scholar]
  14. Benjamin EJ, Wolf PA, D'Agostino RB. 14.  et al. 1998. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–52 [Google Scholar]
  15. Ghanbari H, Baser K, Jongnarangsin K. 15.  et al. 2014. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 11:91503–11 [Google Scholar]
  16. Cappato R, Calkins H, Chen SA. 55.  et al. 2005. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111:1100–5 [Google Scholar]
  17. Cox JL, Jaquiss RD, Schuessler RB, Boineau JP. 16.  1995. Modification of the Maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the Maze III procedure. J. Thorac. Cardiovasc. Surg. 110:485–95 [Google Scholar]
  18. Haïssaguerre M, Jaïs P, Shah DC. 17.  et al. 1996. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J. Cardiovasc. Electrophysiol. 7:1132–44 [Google Scholar]
  19. Swartz J, Perrersels G, Silvers J. 18.  et al. 1994. A catheter based curative approach to atrial fibrillation in humans. Circulation 90:I–335 (Abstr.) [Google Scholar]
  20. Haïssaguerre M, Jaïs P, Shah DC. 19.  et al. 1998. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339:659–66 [Google Scholar]
  21. Nakagawa H, Yamanashi WS, Pitha JV. 20.  et al. 1995. Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. Circulation 91:2264–73 [Google Scholar]
  22. Hussein AA, Barakat AF, Saliba WI. 21.  et al. 2017. Persistent atrial fibrillation ablation with or without contact force sensing. J. Cardiovasc. Electrophysiol. 28:5483–88 [Google Scholar]
  23. Ullah W, McLean A, Tayebjee MH. 22.  et al. 2016. Randomized trial comparing pulmonary vein isolation using the SmartTouch catheter with or without real-time contact force data. Heart 13:1761–67 [Google Scholar]
  24. Pedrote A, Arana-Rueda E, Arce-León A. 23.  et al. 2016. Impact of contact force monitoring in acute pulmonary vein isolation using an anatomic approach. A randomized study. Pacing Clin. Electrophysiol. 39:361–69 [Google Scholar]
  25. Lerman BB, Markowitz SM, Liu CF. 24.  et al. 2017. Fluoroless catheter ablation of atrial fibrillation. Heart Rhythm 14:6928–34 [Google Scholar]
  26. Kuck KH, Brugada J, Fürnkranz A. 25.  et al. 2016. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N. Engl. J. Med. 374:2235–45 [Google Scholar]
  27. Szilágyi J, Marcus GM, Badhwar N. 26.  et al. 2017. Atrial fibrillation patients with isolated pulmonary veins: Is sinus rhythm achievable?. J. Cardiovasc. Electrophysiol. 28:754–61 [Google Scholar]
  28. Verma A, Jiang CY, Betts TR. 27.  et al. 2015. Approaches to catheter ablation for persistent atrial fibrillation. N. Engl. J. Med. 372:1812–22 [Google Scholar]
  29. Li WJ, Bai YY, Zhang HY. 28.  et al. 2011. Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation: a meta-analysis. Circ. Arrhythm. Electrophysiol. 4:143–48 [Google Scholar]
  30. Wu SH, Jiang WF, Gu J. 29.  et al. 2013. Benefits and risks of additional ablation of complex fractionated atrial electrograms for patients with atrial fibrillation: a systematic review and meta-analysis. Int. J. Cardiol. 169:35–43 [Google Scholar]
  31. Wynn GJ, Das M, Bonnett LJ. 30.  et al. 2014. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ. Arrhythm. Electrophysiol. 7:841–52 [Google Scholar]
  32. Sawhney N, Anousheh R, Chen W, Feld GK. 31.  2010. Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3:243–48 [Google Scholar]
  33. Katritsis DG, Giazitzoglou E, Zografos T. 32.  et al. 2011. Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. Heart Rhythm 8:672–78 [Google Scholar]
  34. Katritsis D, Giazitzoglou E, Sougiannis D. 33.  et al. 2009. Complex fractionated atrial electrograms at anatomic sites of ganglionated plexi in atrial fibrillation. Europace 11:308–15 [Google Scholar]
  35. Narayan SM, Krummen DE, Shivkumar K. 34.  et al. 2012. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J. Am. Coll. Cardiol. 60:7628–36 [Google Scholar]
  36. Steinberg JS, Shah Y, Bhatt A. 35.  et al. 2017. Focal impulse and rotor modulation: acute procedural observations and extended clinical follow-up. Heart Rhythm 14:192–97 [Google Scholar]
  37. Buch E, Share M, Tung R. 36.  et al. 2016. Long-term clinical outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: a multicenter experience. Heart Rhythm 13:636–41 [Google Scholar]
  38. Di Biase L, Burkhardt D, Santangeli P. 37.  et al. 2014. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the “COMPARE” randomized trial. Circulation 129:252638–44 [Google Scholar]
  39. Latchamsetty R, Gautam S, Bhakta D. 38.  et al. 2011. Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. Heart Rhythm 8:805–8 [Google Scholar]
  40. Calkins H, Willems S, Gerstenfeld EP. 39.  et al. 2017. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N. Engl. J. Med. 376:1627–36 [Google Scholar]
  41. Pappone C, Augello G, Sala S. 40.  et al. 2006. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J. Am. Coll. Cardiol. 48:2340–47 [Google Scholar]
  42. Nademanee K, McKenzie J, Kosar E. 41.  et al. 2004. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J. Am. Coll. Cardiol. 43:2044–53 [Google Scholar]
  43. Jaïs P, Cauchemez B, Macle L. 42.  et al. 2008. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118:2498–505 [Google Scholar]
  44. Oral H, Chugh A, Good E. 43.  et al. 2006. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation 113:1824–31 [Google Scholar]
  45. Brooks AG, Stiles MK, Laborderie J. 44.  et al. 2010. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm 7:835–46 [Google Scholar]
  46. Latchamsetty R, Morady F. 45.  2013. Long-term benefits following catheter ablation of atrial fibrillation. Circ. J. 77:1091–96 [Google Scholar]
  47. Ouyang F, Tilz R, Chun J. 46.  et al. 2010. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 122:2368–77 [Google Scholar]
  48. Medi C, Sparks PB, Morton JB. 47.  et al. 2011. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. J. Cardiovasc. Electrophysiol. 22:137–41 [Google Scholar]
  49. Tilz RR, Rillig A, Thum AM. 48.  et al. 2012. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J. Am. Coll. Cardiol. 60:1921–29 [Google Scholar]
  50. Sorgente A, Tung P, Wylie J, Josephson ME. 49.  2012. Six year follow-up after catheter ablation of atrial fibrillation: a palliation more than a true cure. Am. J. Cardiol. 109:1179–86 [Google Scholar]
  51. Weerasooriya R, Khairy P, Litalien J. 50.  et al. 2011. Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up?. J. Am. Coll. Cardiol. 57:160–66 [Google Scholar]
  52. Steinberg JS, Palekar R, Sichrovsky T. 51.  et al. 2014. Very long-term outcome after initially successful catheter ablation of atrial fibrillation. Heart Rhythm 11:771–76 [Google Scholar]
  53. Calkins H, Kuck KH, Cappato R. 52.  et al. 2012. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation. Europace 14:528–606 [Google Scholar]
  54. Jalife J, Berenfeld O, Mansour M. 53.  2002. Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. Cardiovasc. Res. 54:204–16 [Google Scholar]
  55. Allessie M, Ausma J, Schotten U. 54.  2002. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 54:230–46 [Google Scholar]
  56. Pontoppidan J, Nielsen JC, Poulsen SH, Hansen PS. 56.  2009. Symptomatic and asymptomatic atrial fibrillation after pulmonary vein ablation and the impact on quality of life. Pacing Clin. Electrophysiol. 32:717–26 [Google Scholar]
  57. Cha YM, Redfield MM, Shen WK, Gersh BJ. 57.  2004. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109:2839–43 [Google Scholar]
  58. Benjamin EJ, Levy D, Vaziri SM. 58.  et al. 1994. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271:840–44 [Google Scholar]
  59. Vermes E, Tardif JC, Bourassa MG. 59.  et al. 2003. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–31 [Google Scholar]
  60. Maggioni AP, Latini R, Carson PE. 60.  et al. 2005. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 149:548–57 [Google Scholar]
  61. Ehrlich JR, Hohnloser SH, Nattel S. 61.  2006. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J. 27:512–18 [Google Scholar]
  62. Mayyas F, Alzoubi KH, Van Wagoner DR. 62.  2013. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int. J. Cardiol. 168:5135–42 [Google Scholar]
  63. Swedberg K, Zannad F, McMurray JJ. 63.  et al. 2012. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J. Am. Coll. Cardiol. 59:1598–603 [Google Scholar]
  64. Gami AS, Pressman G, Caples SM. 64.  et al. 2004. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110:364–67 [Google Scholar]
  65. Fein AS, Shvilkin A, Shah D. 65.  et al. 2013. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J. Am. Coll. Cardiol. 62:300–5 [Google Scholar]
  66. Kanagala R, Murali NS, Friedman PA. 66.  et al. 2003. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 107:2589–94 [Google Scholar]
  67. Pathak RK, Elliott A, Middeldorp ME. 67.  et al. 2015. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: the CARDIO-FIT study. J. Am. Coll. Cardiol. 66:985–96 [Google Scholar]
  68. Wanahita N, Messerli FH, Bangalore S. 68.  et al. 2008. Atrial fibrillation and obesity—results of a meta-analysis. Am. Heart J. 155:310–15 [Google Scholar]
  69. Du X, Dong J, Ma C. 69.  2017. Is atrial fibrillation a preventable disease?. J. Am. Coll. Cardiol. 69:1968–82 [Google Scholar]
  70. Conen D, Tedrow UB, Cook NR. 70.  et al. 2008. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 300:2489–96 [Google Scholar]
  71. Frost L, Vestergaard P. 71.  2004. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch. Intern. Med. 164:1993–98 [Google Scholar]
  72. Larsson SC, Drca N, Wolk A. 72.  2014. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J. Am. Coll. Cardiol. 64:281–89 [Google Scholar]
  73. Qiao Y, Shi R, Hou B. 73.  et al. 2015. Impact of alcohol consumption on substrate remodeling and ablation outcome of paroxysmal atrial fibrillation. J. Am. Heart Assoc. 4:11e002349 [Google Scholar]
  74. Chamberlain AM, Agarwal SK, Folsom AR. 74.  et al. 2011. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 8:1160–66 [Google Scholar]
  75. Psaty BM, Manolio TA, Kuller LH. 75.  et al. 1997. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96:2455–61 [Google Scholar]
  76. Verdecchia P, Staessen JA, Angeli F. 76.  et al. 2009. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374:525–33 [Google Scholar]
  77. Eaker ED, Sullivan LM, Kelly-Hayes M. 77.  et al. 2004. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation 109:1267–71 [Google Scholar]
  78. Hansson A, Madsen-Härdig B, Olsson SB. 78.  2004. Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance. BMC Cardiovasc. Disord. 4:13 [Google Scholar]
  79. Huxley RR, Filion KB, Konety S, Alonso A. 79.  2011. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am. J. Cardiol. 108:56–62 [Google Scholar]
  80. Zakeri R, Van Wagoner DR, Calkins H. 80.  et al. 2017. The burden of proof: the current state of atrial fibrillation prevention and treatment trials. Heart Rhythm 14:5763–82 [Google Scholar]
  81. Pathak RK, Middeldorp ME, Lau DH. 81.  et al. 2014. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J. Am. Coll. Cardiol. 64:2222–31 [Google Scholar]
/content/journals/10.1146/annurev-med-041316-090015
Loading
/content/journals/10.1146/annurev-med-041316-090015
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error